Organisation of neoplastic haematopathology services: A UK perspective

Pathology

Volumn 37, Issue 6, 2005, Pages 479-492

  Jack, Andrew ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

FISH; Flow cytometry; Haematopathology; Hematopathology; Leukaemia; Lymphoma

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMATINIB; PREDNISONE; RITUXIMAB; VINCRISTINE;

B CELL LYMPHOMA; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOHISTOLOGY; INFORMATION TECHNOLOGY; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOMA; MINIMAL RESIDUAL DISEASE; MORPHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; REVIEW; SKILL MIX; UNITED KINGDOM; WORLD HEALTH ORGANIZATION;

EID: 29744461875     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020500368360     Document Type: Article

References (79)

1. Lester JF, Dojcinov SD, Attanoos RL, et al. The clinical impact of expert pathological review on lymphoma management: a regional experience. Br J Haematol 2003; 123: 463-8.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
3. O'Brien SG, Deininger MW. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol 2003; 40: 26-30.
4. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin lymphoma. Semin Oncol 2002; 29: 18-22.
5. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-84.
6. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245-7.
7. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452-3.
8. Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003; 97: 2748-59.
9. Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998; 92: 3562-8.
10. Hagemeister FB. Mantle cell lymphoma: non-myeloablative versus dose-intensive therapy. Leuk Lymphoma 2003; 44 (Suppl 3), S69-S75.
11. Lee JH, Lee JH, Kang YK, et al. Allogeneic non-myeloablative stem cell transplantation for the patients with heavily pre-treated refractory lymphoma. Haematologica 2001; 86: 1114-5.
12. Kim SH, Jung KC, Shin YK, et al. The enhanced reactivity of endogenous biotin-like molecules by antigen retrieval procedures and signal amplification with tyramine. Histochem J 2002; 34: 97-103.
13. Mayer G, Bendayan M. Amplification methods for the immunolocalization of rare molecules in cells and tissues. Prog Histochem Cytochem 2001; 36: 3-85.
14. McLachlan CS, Jusuf PR, Rummery N, et al. Tyramide signal amplification enhances the detectable distribution of connexin-43 positive gap junctions across the ventricular wall of the rabbit heart. Arch Histol Cytol 2003; 66: 359-65.
15. McNicol AM, Richmond JA. Optimizing immunohistochemistry: antigen retrieval and signal amplification. Histopathology 1998; 32: 97-103.
16. Werner M, Von Wasielewski R, Komminoth P. Antigen retrieval, signal amplification and intensification in immunohistochemistry. Histochem Cell Biol 1996; 105: 253-60.
17. Blythe D, Hand NM, Jackson P, et al. Use of methyl methacrylate resin for embedding bone marrow trephine biopsy specimens. J Clin Pathol 1997; 50: 45-9.
18. Marafioti T, Pozzobon M, Hansmann ML, et al. Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma. Leukemia 2005; 19: 856-61.
19. Marafioti T, Jones M, Facchetti F, et al. Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology. Blood 2003; 102: 2868-76.
20. Cullen MJ, Richards SJ, O'Connor SJ, et al. Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence. Cancer Genet Cytogenet 2004; 148: 176-7.
21. O'Connor SJ, Forsyth PD, Dalal S, et al. The rapid diagnosis of acute promyelocytic leukaemia using PML (5E10) monoclonal antibody. Br J Haematol 1997; 99: 597-604.
22. San Miguel JF, Vidriales MB, Orfao A. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML). Best Pract Res Clin Haematol 2002; 15: 105-18.
23. Szczepanski T, Orfao A, van dV, V, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409-17.
24. Vidriales MB, San Miguel JF, Orfao A, Coustan-Smith E, Campana D. Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol 2003; 16: 599-612.
25. Vidriales MB, Perez JJ, Lopez-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003; 101: 4695-700.
26. De Zen L, Orfao A, Cazzaniga G, et al. Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia 2000; 14: 1225-31.
27. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-317.
28. Barrans SL, Evans PA, O'Connor SJ, et al. The detection of t(14;18) in archival lymph nodes: development of a fluorescence in situ hybridization (FISH)-based method and evaluation by comparison with polymerase chain reaction. J Mol Diagn 2003; 5: 168-75.
29. Flora R, Grimwade D. Real-time quantitative RT-PCR to detect fusion gene transcripts associated with AML. Methods Mol Med 2004; 91: 151-73.
30. Grimwade D. The significance of minimal residual disease in patients with t(15;17). Best Pract Res Clin Haematol 2002; 15: 137-58.
31. Yin JA, Frost L. Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia. Curr Oncol Rep 2003; 5: 399-404.
32. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005; 11: 3425-32.
33. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204-5.
34. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101: 97-100.
35. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61.
36. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-8.
37. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90.
38. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88.
39. Huntly BJ, Reid AG, Bench AJ, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98: 1732-8.
40. Bacher U, Haferlach T, Kern W, et al. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 2005; 84: 250-7.
41. Bacher U, Kern W, Schnittger S, et al. Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia. Leuk Lymphoma 2005; 46: 357-66.
42. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002; 107: 76-94.
43. Deininger MW. Cytogenetic studies in patients on imatinib. Semin Hematol 2003; 40: 50-5.
44. Feldman E, Najfeld V, Schuster M, et al. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 2003; 31: 702-7.
45. Hamblin TJ, Orchard JA, Gardiner A, et al. Immunoglobulin V genes and CD38 expression in CLL. Blood 2000; 95: 2455-7.
46. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-75.
47. Durig J, Nuckel H, Cremer M, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003; 17: 2426-34.
48. Murashige N, Kami M, Takaue Y. ZAP-70 in chronic lymphocytic leukemia. N Engl J Med 2003; 349: 506-7.
49. Garcia-Manero G. Chromosomal abnormalities in chronic lymphocytic leukemia. N Engl J Med 2001; 344: 1254.
50. Oscier DG. Cytogenetics and molecular genetics of chronic lymphocytic leukaemia. Haematologica 1999; 84 (Suppl EHA-4): 88-91.
51. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278-81.
52. Sturm I, Bosanquet AG, Hermann S, et al. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003; 10: 477-84.
53. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
54. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-62.
55. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
56. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136-43.
57. Barrans SL, Evans PA, O'Connor SJ, et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 2003; 9: 2133-9.
58. Barrans SL, O'Connor SJ, Evans PA, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002; 117: 322-32.
59. Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005; 11: 1065-72.
60. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma patients with poor outcome. Blood 2004; 104: 2933-5.
61. Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem cell maintenance. Blood 2005; 106: 899-902.
62. Onciu M, Behm FG, Downing JR, et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 2003; 102: 2642-4.
63. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-9.
64. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999; 107: 69-79.
65. Davies FE, Rawstron AC, Owen RG, Morgan GJ. Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Haematol 2002; 15: 197-222.
66. Owen RG, Rawstron AC. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice. Br J Haematol 2005; 128: 732-3.
67. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29-35.
68. Sanz MA, Sempere A. Immunophenotyping of AML and MDS and detection of residual disease. Baillieres Clin Haematol 1996; 9: 35-55.
69. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29-35.
70. Hardling M, Wei Y, Palmqvist L, et al. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate. Med Oncol 2004; 21: 349-58.
71. Hughes T, Branford S. Molecular monitoring of chronic myeloid leukemia. Semin Hematol 2003; 40: 62-8.
72. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003; 9: 160-6.
73. Iqbal Z, Siddiqui RT, Qureshi JA. Two different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: a case report. Biol Proced Online 2004; 6: 144-8.
74. Roche-Lestienne C, Preudhomme C. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol 2003; 40: 80-2.
75. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-57.
76. Gribben JG, Nadler LM, Purging of autologous bone marrow in the treatment of non-Hodgkin lymphoma. Important Adv Oncol 1993, 139-56.
77. Evans PA, Short MA, Owen RG, et al. Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 3616-27.
78. Owen RG, Goulden NJ, Oakhill A, et al. Comparison of fluorescent consensus IgH PCR and allele-specific oligonucleotide probing in the detection of minimal residual disease in childhood ALL. Br J Haematol 1997; 97: 457-9.
79. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74.